Physician profile
Mark Leondires
NPI 1063437275
$30,962.18
in general payments reported to CMS, 2019-2025
9 companies · $140 in 2025
The $140 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $458 · 2020: $182 · 2021: $2,309 · 2022: $7,229 · 2023: $19K · 2024: $1,375 · 2025: $140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $20K · Food and Beverage: $633.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $20,150.00 |
| Food and Beverage | $633.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $22,006.40 | 2019-2025 | |
| Ferring Pharmaceuticals INC. | $7,541.90 | 2019-2025 | Menopur |
| Merck Kgaa | $1,090.00 | 2024 | |
| Coopersurgical, INC. | $128.61 | 2021-2025 | Stripper |
| Merck Sharp & Dohme LLC | $95.90 | 2019-2021 | |
| Organon LLC | $48.12 | 2022-2024 | |
| Vitrolife INC. | $37.79 | 2022 | |
| Galen US INC | $13.46 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Leondires listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.